Skip Navigation

Your Environment. Your Health.

Innate Immunity Signal Transduction in Human Leukocytes

Open for Recruitment

Study Background

Innate Immunity Signal Transduction in Human Leukocytes

Open for Recruitment

The Innate Immunity Signal Transduction in Human Leukocytes is a research study to determine the response of immune cells from the bloodstream.

This study will investigate the response of immune cells to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.

For more information on this study, please visit the Clinical Trials Study page.

This content is available to use on your website.
Please visit NIEHS Syndication to get started.

Eligibility

  • Ages Eligible for Study: 18 Years to 65 Years
  • Genders Eligible for Study: Both
  • Accepts Healthy Volunteers: Yes

Inclusion Criteria:

  1. Normal, healthy adult donors as judged by screening questionnaire 
  2. Nonpregnant 
  3. Weighing at least 110 lbs 
  4. Aged 18-65 years of age 

Exclusion Criteria: 

By questionnaire: 

  1. Feeling ill within the last 24 hours.
  2. Alcohol consumption in the last 24 hours.
  3. Visit to the dentist in the last 24 hours.
  4. A doctor visit for illness or vaccination in the last 2 weeks.
  5. Diarrhea in the last 2 weeks.
  6. Recurrent fever (4 weeks).
  7. Pregnant or suspected pregnancy in the last 6 weeks.
  8. Blood or plasma donation that will cause the participant to exceed 550ml of blood in the last 8 weeks.
  9. Receiving a blood donation in the past 12 months.
  10. Bleeding disorder.
  11. Anemia.
  12. Heart problems. 
  13. Insulin dependent diabetes.
  14. Problems with blood donation.
  15. Risk of or evidence of Creutzfeldt-Jacob Disease in the family.
  16. Use of selected medications within the preceding 5 days unless the researcher receiving the samples states otherwise (NSAIDS/aspirin/Tylenol, antidepressants, antihistamines, corticosteroids, HMG CoA reductase inhibitors, and antihypertensives). 

By exam: 

  1. Temperature over 99.5 F.
  2. Blood pressure less than 90/50.
  3. Blood pressure higher than 170/95 mm
  4. Pulse rate less than 50 or greater than 100 beats/minute.

What will you do?

  • Qualified participants that donate up to 320 ml of blood, approximately 1 1/3 cups, will receive $45 per donation.
  • Each participant can donate up to every 8 weeks.

What will NIEHS do?

  • We are conducting a study of human blood cell function and ask donors to donate up to 320 ml of blood (approximately 1 1/2 cups).
  • Qualified participants will be provided $45 per donation.

Study / Trial Location

Sample collections are conducted at the NIEHS Clinical Research Unit located in Research Triangle Park, North Carolina.

Protocol Number: 07-E-0023

Enrollment and Contact Information

To volunteer or learn more, contact Nicole Edwards at (919) 316-4976.

Principal Investigator

Michael B. Fessler, M.D.
Michael B. Fessler, M.D.
Acting Chief, Immunity, Inflammation, and Disease Laboratory and Principal Investigator
Tel 919-541-3701
Fax 919-541-4133
fesslerm@niehs.nih.gov
P.O. Box 12233
Mail Drop D2-01
Durham, N.C. 27709
Stavros Garantziotis, M.D.
Stavros Garantziotis, M.D.
Medical Director, NIEHS Clinical Research Unit and Principal Investigator
Tel 919-541-9859
Fax 919-541-9854
garantziotis@niehs.nih.gov
P.O. Box 12233
Mail Drop CU-01
Durham, N.C. 27709